Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

Neurology. 2007 Feb 27;68(9):688-90. doi: 10.1212/01.wnl.0000255937.27012.ee.

Abstract

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents, Alkylating / administration & dosage
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality*
  • Dacarbazine / administration & dosage
  • Dacarbazine / analogs & derivatives*
  • Disease-Free Survival
  • Feasibility Studies
  • Female
  • Glioma / drug therapy*
  • Glioma / mortality*
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Risk Assessment / methods*
  • Risk Factors
  • Survival Analysis
  • Survival Rate
  • Temozolomide
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide